We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Edwards Lifesciences Stock Up 22.1% in a Year: What's Driving It?
Read MoreHide Full Article
Key Takeaways
EW shares jumped 22.1% in a year, outperforming the industry's 3.8% decline and tracking the S&P 500.
Edwards Lifesciences saw strong TMTT momentum, driven by global adoption of PASCAL and EVOQUE systems.
EW's TAVR sales topped $1B for the fifth straight quarter, reflecting strong demand for SAPIEN therapy.
Edwards Lifesciences (EW - Free Report) has delivered an impressive return over the past year, with shares rallying 22.1%. The stock comfortably outpaced the industry’s 3.8% fall and closely tracked the S&P 500 composite’s 23.5% rise.
Carrying a Zacks Rank #2 (Buy) at present, the renowned global structural heart innovation company has seen consistent growth in the Transcatheter Mitral and Tricuspid Therapies (“TMTT”) segment over the past few quarters while efficiently scaling its fast-growing businesses. The company’s Transcatheter Aortic Valve Replacement (“TAVR”) platform benefits from advances in new technologies such as RESILIA and increased global adoption. The Surgical Structural Heart business also sees robust uptake of its premium surgical technologies worldwide.
Irvine, CA-based Edwards Lifesciences deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. On Sept. 3, 2024, Edwards Lifesciences completed the sale of its Critical Care product group to Becton, Dickinson, and Company for $4.2 billion in cash, strengthening balance sheet flexibility to invest in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure.
Factors Supporting Edwards’ Price Rally
The rally in the share price can be linked to the company’s ongoing momentum in the TMTT segment, led by continued global adoption of the PASCAL and EVOQUE systems. Backed by the insights gained from clinical trials and real-world experiences, Edwards constructed a strategic portfolio of leading transcatheter technologies to provide both repair and replacement solutions for mitral and tricuspid patients. The company continues to scale its fast-growing business and remains pleased with its trajectory over the past several years.
Under the finalized National Coverage Determination, EVOQUE became eligible in March 2025 for all Medicare beneficiaries with symptomatic tricuspid regurgitation (TR). In April 2025, the SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR), who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy.
Image Source: Zacks Investment Research
TAVR sales exceeded $1 billion for the fifth consecutive quarter in the fourth quarter of 2025. The performance reflects clinicians' elevated focus on SAPIEN therapy and proactive disease management of patients suffering from severe aortic stenosis. Edwards' strong competitive position and pricing remained stable globally. In Europe, results reflected healthy underlying TAVR procedure growth and its consistent execution across the region.
Following the CE Mark for the Alterra system for congenital heart patients, Edwards is rolling out this therapy in Europe, and initial feedback from clinicians has been positive.
In 2025, growth in the Surgical Structural Heart business was driven by the strong global adoption of Edwards’ premium resilient technologies, including INSPIRIS, MITRIS and KONECT. The company continues to see positive procedure growth globally for the many patients treated surgically, including those undergoing complex procedures. Edwards has been continuously generating evidence to expand the RESILIA portfolio. The company also made progress in advancing important innovations worldwide, including the CE Mark approval for KONECT in Europe and the launch of MITRIS in China.
Concerns for EW Stock
The industrywide increase in inflationary pressure, supply constraints stemming from geopolitical complications and regulatory changes are weighing heavily on Edwards’ operating results. The business is also currently experiencing staffing shortages within the hospital systems.
A Glance at EW’s Estimates
The Zacks Consensus Estimate for Edwards Lifesciences’ 2026 and 2027 earnings per share (EPS) is expected to increase 14.8% and 12.2%, respectively, to $2.94 and $3.30. In the past 30 days, the Zacks Consensus Estimate for the company's 2026 EPS has risen 2.1%.
Revenues for 2026 are projected to grow 9.6% to $6.65 billion, followed by a 9.8% jump to $7.30 billion in 2027.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s -0.7% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 22.3% against the industry’s 3.8% fall in the past year.
Intuitive Surgical, sporting a Zacks Rank #1, has an earnings yield of 2.1% against the industry’s -0.7% yield. Shares of the company have dropped 0.9% compared with the industry’s 39% fall. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.
Phibro Animal Health, sporting a Zacks Rank #1 at present, has an earnings yield of 6.1% compared with the industry’s 2.6% yield. Shares of the company have climbed 130.6% against the industry’s 17.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.2%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Edwards Lifesciences Stock Up 22.1% in a Year: What's Driving It?
Key Takeaways
Edwards Lifesciences (EW - Free Report) has delivered an impressive return over the past year, with shares rallying 22.1%. The stock comfortably outpaced the industry’s 3.8% fall and closely tracked the S&P 500 composite’s 23.5% rise.
Carrying a Zacks Rank #2 (Buy) at present, the renowned global structural heart innovation company has seen consistent growth in the Transcatheter Mitral and Tricuspid Therapies (“TMTT”) segment over the past few quarters while efficiently scaling its fast-growing businesses. The company’s Transcatheter Aortic Valve Replacement (“TAVR”) platform benefits from advances in new technologies such as RESILIA and increased global adoption. The Surgical Structural Heart business also sees robust uptake of its premium surgical technologies worldwide.
Irvine, CA-based Edwards Lifesciences deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. On Sept. 3, 2024, Edwards Lifesciences completed the sale of its Critical Care product group to Becton, Dickinson, and Company for $4.2 billion in cash, strengthening balance sheet flexibility to invest in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure.
Factors Supporting Edwards’ Price Rally
The rally in the share price can be linked to the company’s ongoing momentum in the TMTT segment, led by continued global adoption of the PASCAL and EVOQUE systems. Backed by the insights gained from clinical trials and real-world experiences, Edwards constructed a strategic portfolio of leading transcatheter technologies to provide both repair and replacement solutions for mitral and tricuspid patients. The company continues to scale its fast-growing business and remains pleased with its trajectory over the past several years.
Under the finalized National Coverage Determination, EVOQUE became eligible in March 2025 for all Medicare beneficiaries with symptomatic tricuspid regurgitation (TR). In April 2025, the SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR), who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy.
Image Source: Zacks Investment Research
TAVR sales exceeded $1 billion for the fifth consecutive quarter in the fourth quarter of 2025. The performance reflects clinicians' elevated focus on SAPIEN therapy and proactive disease management of patients suffering from severe aortic stenosis. Edwards' strong competitive position and pricing remained stable globally. In Europe, results reflected healthy underlying TAVR procedure growth and its consistent execution across the region.
Following the CE Mark for the Alterra system for congenital heart patients, Edwards is rolling out this therapy in Europe, and initial feedback from clinicians has been positive.
In 2025, growth in the Surgical Structural Heart business was driven by the strong global adoption of Edwards’ premium resilient technologies, including INSPIRIS, MITRIS and KONECT. The company continues to see positive procedure growth globally for the many patients treated surgically, including those undergoing complex procedures. Edwards has been continuously generating evidence to expand the RESILIA portfolio. The company also made progress in advancing important innovations worldwide, including the CE Mark approval for KONECT in Europe and the launch of MITRIS in China.
Concerns for EW Stock
The industrywide increase in inflationary pressure, supply constraints stemming from geopolitical complications and regulatory changes are weighing heavily on Edwards’ operating results. The business is also currently experiencing staffing shortages within the hospital systems.
A Glance at EW’s Estimates
The Zacks Consensus Estimate for Edwards Lifesciences’ 2026 and 2027 earnings per share (EPS) is expected to increase 14.8% and 12.2%, respectively, to $2.94 and $3.30. In the past 30 days, the Zacks Consensus Estimate for the company's 2026 EPS has risen 2.1%.
Revenues for 2026 are projected to grow 9.6% to $6.65 billion, followed by a 9.8% jump to $7.30 billion in 2027.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s -0.7% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 22.3% against the industry’s 3.8% fall in the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical, sporting a Zacks Rank #1, has an earnings yield of 2.1% against the industry’s -0.7% yield. Shares of the company have dropped 0.9% compared with the industry’s 39% fall. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.
Phibro Animal Health, sporting a Zacks Rank #1 at present, has an earnings yield of 6.1% compared with the industry’s 2.6% yield. Shares of the company have climbed 130.6% against the industry’s 17.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.2%.